




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61M 16/00</b>		<b>A1</b>	(11) International Publication Number: <b>WO 99/24099</b> (43) International Publication Date: 20 May 1999 (20.05.99)
(21) International Application Number: <b>PCT/AU98/00950</b> (22) International Filing Date: 6 November 1998 (06.11.98) (30) Priority Data: PP 0269                      7 November 1997 (07.11.97)      AU (71) Applicant (for all designated States except US): <b>RESMED LIMITED [AU/AU]; 82 Waterloo Road, North Ryde, NSW 2113 (AU).</b> (72) Inventors; and (75) Inventors/Applicants (for US only): <b>BERTHON-JONES, Michael [AU/AU]; 7, Leonay Parade, Leonay, NSW 2750 (AU). FARRUGIA, Steven, Paul [AU/AU]; 6A Elwin Street, Peakhurst, NSW 2210 (AU).</b> (74) Agent: <b>SPRUSON &amp; FERGUSON; G.P.O Box 3898, Sydney, NSW 2001 (AU).</b>		(81) Designated States: <b>AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b>  <b>Published</b> <i>With international search report.</i>	

(54) Title: ADMINISTRATION OF CPAP TREATMENT PRESSURE IN PRESENCE OF APNEA



**(57) Abstract**

CPAP treatment apparatus is disclosed having a controllable flow generator (34, 38, 40) operable to produce breathable gas at a treatment pressure elevated above atmosphere to a patient by a delivery tube (32) coupled to a mask (30) having connection with a patient's airway. A sensor (44, 50, 56, 58) generates a signal representative of patient respiratory flow, that is provided to a controller (54, 62, 64). The controller (54, 62, 64) is operable to determine the occurrence of an apnea from a reduction in respiratory airflow below a threshold, and if an apnea has occurred, to determine the duration of the apnea and to cause the flow generator (34, 38) to increase the treatment pressure by an amount which is an increasing function of the duration of the apnea, and a decreasing function of the treatment pressure immediately before the apnea.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## Administration of CPAP Treatment Pressure in Presence of Apnea

### Field of the Invention

5           This invention relates to the administration of continuous positive airway pressure (CPAP) treatment for partial or complete upper airway obstruction.

### Background of the Invention

10           In the Sleep Apnea syndrome a person stops breathing during sleep. Cessation of airflow for more than 10 seconds is called an "apnea". Apneas lead to decreased blood oxygenation and thus to disruption of sleep. Apneas are traditionally (but confusingly) categorized as either central, where there is no respiratory effort, or obstructive, where there is respiratory effort. With some central apneas, the airway is  
15           open, and the subject is merely not attempting to breathe. Conversely, with other central apneas and all obstructive apneas, the airway is closed. The occlusion is usually at the level of the tongue or soft palate. The airway may also be partially obstructed (i.e. narrowed or partially patent). This also leads to decreased ventilation (hypopnea), decreased blood oxygenation and disturbed sleep.

20           The common form of treatment of these syndromes is the administration of Continuous Positive Airway Pressure (CPAP). The procedure for administering CPAP treatment has been well documented in both the technical and patent literature. An early description can be found in U.S. Patent No. 4,944,310 (Sullivan). Briefly stated,  
25           CPAP treatment acts as a pneumatic splint of the airway by the provision of a positive pressure, usually in the range 4 - 20 cm H<sub>2</sub>O. The air is supplied to the airway by a motor driven blower whose outlet passes via an air delivery hose to a nose (or nose and/or mouth) mask sealingly engaged to a patient's face. An exhaust port is provided in the delivery tube proximate to the mask. The mask can take the form of a nose  
30           and/or face mask or nasal prongs, pillows or cannulae.

          Various techniques are known for sensing and detecting abnormal breathing patterns indicative of obstructed breathing. U.S. Patent No. 5,245,995 (Sullivan et al), for example, describes how snoring and abnormal breathing patterns can be detected by  
35           inspiration and expiration pressure measurements made while a subject is sleeping, thereby leading to early indication of preobstructive episodes or other forms of breathing disorder. Particularly, patterns of respiratory parameters are monitored, and CPAP pressure is raised on the detection of pre-defined patterns to provide increased

airway pressure to, ideally, subvert the occurrence of the obstructive episodes and the other forms of breathing disorder.

Automatic detection of partial upper airway obstruction and pre-emptive  
5 adjustment of nasal CPAP pressure works to prevent frank obstructive apneas in the majority of subjects with obstructive sleep apnea syndrome. However, some subjects with severe disease progress directly from a stable open upper airway to a closed airway apnea with complete airway closure, with little or no intervening period of  
10 partial obstruction. Therefore it is useful for an automatically adjusting CPAP system to also respond to a closed airway apnea by an increase in CPAP pressure. However, it is not desirable to increase CPAP pressure in response to open airway apneas, firstly because this leads to an unnecessarily high pressure, and secondly because the high pressure can reflexly cause yet further open airway apneas, leading to a vicious circle of pressure increase.

15 One method for distinguishing open airway apneas (requiring no increase in pressure) from closed airway apneas (requiring a pressure increase) is disclosed in commonly owned European Publication No. 0 651 971 A1 (corresponding to US Patent No. 5,704,345). During an apnea, the mask pressure is modulated at 4 Hz with an  
20 amplitude of the order of 1 cmH<sub>2</sub>O, the induced airflow at 4 Hz is measured, and the conductance of the airway is calculated. A high conductance indicates an open airway. This 'forced oscillation method' requires the ability to modulate the mask pressure at 4 Hz, which increases the cost of the device. Furthermore, the method does not work in the presence of high leak, and can falsely report that the airway is closed if the subject  
25 has a high nasal or intrapulmonary resistance.

The present invention is directed to overcoming or at least ameliorating one or more of the foregoing disadvantages in the prior art.

### 30 Disclosure of the Invention

Therefore, the invention discloses a method for the administration of CPAP treatment pressure comprising the steps of:

- 35 supplying breathable gas to the patient's airway at a treatment pressure;  
determining a measure of respiratory airflow; and  
determining the occurrence of an apnea from a reduction in the measure of respiratory airflow below a threshold, and, if having occurred,  
(i) determining the duration of the apnea; and

(ii) increasing the treatment pressure by an amount which is an increasing function of the duration of the apnea, and a decreasing function of the treatment pressure immediately before the apnea.

- 5 The invention further discloses CPAP treatment apparatus comprising:
- a controllable flow generator operable to produce breathable gas at a pressure elevated above atmosphere;
  - a gas delivery tube coupled to the flow generator;
  - a patient mask coupled to the tube to receive said breathable gas from the flow
  - 10 generator and provide said gas, at a desired treatment pressure, to the patient's airway;
  - a controller operable to receive input signals and to control operation of said flow generator and hence the treatment pressure; and
  - sensor means located to sense patient respiratory airflow and generate a signal input to the controller from which patient respiratory airflow is determined;
  - 15 and wherein said controller is operable to determine the occurrence of an apnea from a reduction in said respiratory airflow below a threshold, and if having occurred, to determine the duration of said apnea and cause said flow generator to increase CPAP treatment pressure by an amount that is an increasing function of said apnea duration, and a decreasing function of the treatment pressure immediately prior to said apnea.

- 20 The invention yet further provides CPAP treatment apparatus comprising:
- a controllable flow generator operable to produce breathable gas to be provided to a patient at a treatment pressure elevated above atmosphere; and
  - a controller operable to receive input signals representing patient respiratory
  - 25 airflow, and to control operation of said flow generator and hence the treatment pressure;
  - and wherein said controller is operable to determine the occurrence of an apnea from a reduction in said respiratory airflow below a threshold, and, if having occurred, to determine the duration of said apnea and cause said flow generator to increase CPAP
  - 30 treatment pressure by an amount that is an increasing function of said apnea duration, and a decreasing function of the treatment pressure immediately prior to said apnea.

- Preferably, the increase in treatment pressure is zero if the treatment pressure before the apnea exceeds a pressure threshold. The increase in pressure below the
- 35 pressure threshold can be an increasing function of the duration of the apnea, multiplied by the difference between the pressure threshold and the current treatment pressure. Further, the increasing function of apnea duration is linear on apnea duration. Advantageously, said increasing function of apnea duration is zero for zero apnea

duration, and exponentially approaches an upper limit as apnea duration goes to infinity.

5       The occurrence of an apnea can be determined by calculating the RMS  
respiratory airflow over a short time interval, calculating the RMS respiratory airflow  
over a longer time interval, and declaring an apnea if the RMS respiratory airflow over  
the short time interval is less than a predetermined fraction of the RMS respiratory  
airflow over the longer time interval. There also can be the further step or action of  
reducing the treatment pressure towards an initial treatment pressure in the absence of a  
10   further apnea.

In a preferred form, said sensor means can comprise a flow sensor, and said  
controller derives respiratory airflow therefrom.

15       In one preferred form said initial treatment pressure is 4 cmH<sub>2</sub>O, said measure  
of respiratory airflow is the two second moving average RMS airflow, and said  
threshold is 25% of the RMS airflow over the preceding 5 minutes. In this preferred  
form, no increase in pressure is made for apneas of less than 10 seconds duration, or  
for apneas where the treatment pressure immediately prior to the apnea is more than 10  
20   cmH<sub>2</sub>O, but otherwise, the lower the treatment pressure immediately prior to the  
apnea, and the longer the apnea, the greater the increase in treatment pressure, up to a  
maximum of 8 cmH<sub>2</sub>O per minute of apnea. In this preferred form, if there is no apnea  
the treatment pressure is gradually reduced towards the initial minimum pressure with a  
time constant of 20 minutes.

25       The method and apparatus can advantageously be used in concert with one or  
more other methods for determining the occurrence of partial upper airway obstruction,  
such that either complete or partial upper airway obstruction can lead to an increase in  
pressure, but once there is no longer either complete or partial obstruction, the pressure  
30   will gradually reduce towards the initial minimum pressure.

In one particularly preferred form, partial obstruction is detected as either the  
presence of snoring, or the presence of characteristic changes in the shape of the  
inspiratory flow-vs-time curve indicative of inspiratory airflow limitation.

35

The method and apparatus can also advantageously be used in concert with the  
'forced oscillation method' for measuring airway patency (referred to above as  
European Publication No. 0 651 971 A1), in which the CPAP pressure is modulated

with an amplitude of for example 1 cmH<sub>2</sub>O at 4 Hz, the induced airflow at 4 Hz is measured, the conductance of the airway calculated by dividing the amplitude of the induced airflow by the pressure modulation amplitude, and the additional requirement imposed that the treatment pressure is only increased if said conductance is greater than  
5 a threshold.

Closed airway apneas are most likely to occur at low CPAP pressures, because high CPAP pressures splint the airway partially or completely open, whereas pressure-induced open airway apneas are most likely to occur at high CPAP pressures, at least  
10 partially because high CPAP pressures increase lung volume and thereby stimulate the Hering-Breuer reflex, leading to inhibition of breathing. Therefore, the lower the existing CPAP pressure, the more likely an apnea is to be of the closed airway variety, and the more appropriate it is to increase the treatment pressure, whereas the higher the existing CPAP pressure, the more likely an apnea is to be of the open airway variety,  
15 and the more appropriate it is to leave the CPAP pressure unchanged. Generally apneas of less than 10 seconds duration are regarded as non-pathological, and there is no need to increase CPAP pressure, whereas very long apneas require treatment. The present invention will correctly increase the CPAP pressure for most closed airway apneas, and correctly leave the CPAP pressure unchanged for most open airway apneas.

20

The present invention can be combined with an independent pressure increase in response to indicators of partial upper airway obstruction such as snoring or changes in shape of the inspiratory flow-time curve. In this way it is possible in most subjects to achieve pre-emptive control of the upper airway, with pressure increases in response  
25 to partial upper airway obstruction preventing the occurrence of closed airway apneas. In the minority of subjects in whom pre-emptive control is not achieved, this combination will also correctly increase the CPAP pressure in response to those closed airway apneas that occur at low CPAP pressure without prior snoring or changes in the shape of the inspiratory flow-time curve. Furthermore, the combination will avoid  
30 falsely increasing the CPAP pressure in response to open airway apneas induced by high pressure.

Some open airway apneas can occur at low pressure. By combining the forced oscillation method with the present invention, with the additional requirement that there  
35 be no increase in pressure if the forced oscillation method detects an open airway, false increases in pressure in response to open airway apneas at low pressure will be largely avoided.

### Brief Description of the Drawings

Embodiments of the invention will now be described with reference to the accompanying drawings, in which:

5 Fig. 1 shows, in diagrammatic form, apparatus embodying the invention;

Fig. 2 shows an alternative arrangement of the apparatus of Fig. 1;

Fig. 3 shows a plot of two pressure change characteristics as a function of apnea duration;

Fig. 4 shows a plot of the apnea duration function;

10 Fig. 5 shows a graph of CPAP treatment pressure versus time for a preferred embodiment of the invention; and

Fig. 6 shows a graph of scaled (normalized) air flow with time for normal and partially obstructed inspiration.

### 15 Detailed Description of Preferred Embodiments and Best Mode

Fig. 1 shows, in diagrammatic form, CPAP apparatus in accordance with one embodiment. A mask 30, whether either a nose mask and/or a face mask, is sealingly fitted to a patient's face. Breathable gas in the form of fresh air, or oxygen enriched  
20 air, enters the mask 30 by flexible tubing 32 which, in turn, is connected with a motor driven turbine 34 to which there is provided an air inlet 36. The motor 38 for the turbine is controlled by a motor-servo unit 40 to commence, increase or decrease the pressure of air supplied to the mask 30 as CPAP treatment. The mask 30 also includes an exhaust port 42 that is close to the junction of the tubing 34 with the mask 30.

25

Interposed between the mask 30 and the exhaust 42 is a linear flow-resistive element 44. In practice, the distance between mask 30 and exhaust 42, including flow resistive element 44 is very short so as to minimize deadspace volume. The mask side of the flow-resistive element 44 is connected by a small bore tube 46 to a mask pressure  
30 transducer 48 and to an input of a differential pressure transducer 50. Pressure at the other side of the flow-resistive element 44 is conveyed to the other input of the differential pressure transducer 50 by another small bore tube 52.

The mask pressure transducer 48 generates an electrical signal in proportion to  
35 the mask pressure, which is amplified by amplifier 52 and passed both to a multiplexer/ADC unit 54 and to the motor-servo unit 40. The function of the signal provided to the motor-servo unit 40 is as a form of feedback to ensure that the actual mask static pressure is controlled to be closely approximate to the set point pressure.



The differential pressure sensed across the linear flow-resistive element 44 is output as an electrical signal from the differential pressure transducer 50, and amplified by another amplifier 56. The output signal from the amplifier 56 therefore represents a measure of the mask airflow. The linear flow-resistive element 44 can be constructed using a flexible-vaned iris. Alternatively, a fixed orifice can be used, in which case a linearization circuit is included in amplifier 52, or a linearization step such as table lookup included in the operation of controller 62.

The output signal from the amplifier 56 is low-pass filtered by the low-pass filter 58, typically with an upper limit of 10 Hz, in order to remove non-respiratory noise. The amplifier 56 output signal is also bandpassed by the bandpass filter 60, and typically in a range of 30 - 100 Hz to yield a snoring signal. The outputs from both the low-pass filter 58 and the bandpass filter 60 are provided to the digitizer (ADC) unit 54. The digitized respiratory airflow (FLOW), snore, and mask pressure ( $P_{\text{mask}}$ ) signals from ADC 54 are passed to a controller 62, typically constituted by a micro-processor based device also provided with program memory and data processing storage memory.

The controller 62 outputs a pressure request signal which is converted to a voltage by DAC 64, and passed to the motor-servo unit 40. This signal therefore represents the set point pressure  $P_{\text{set}}(t)$  to be supplied by the turbine 34 to the mask 30 in the administration of CPAP treatment. The controller 62 is programmed to perform a number of processing functions, as presently will be described.

As an alternative to the mask pressure transducer 48, a direct pressure/electrical solid state transducer (not shown) can be mounted from the mask with access to the space therewithin, or to the air delivery tubing 32 proximate the point of entry to the mask 30.

Further, it may not be convenient to mount the flow transducer 44 at or near the mask 30, nor to measure the mask pressure at or near the mask. An alternative arrangement, where the flow and pressure transducers are mounted at or near the air pressure generator (in the embodiment being the turbine 34) is shown in Fig. 2.

The pressure  $p_g(t)$  occurring at the pressure generator 34 outlet is measured by a pressure transducer 70. The flow  $f_g(t)$  through tubing 32 is measured with flow sensor 72 provided at the output of the turbine 34. The pressure loss along tubing 32 is

calculated in element 74 from the flow through the tube  $f_g(t)$ , and a knowledge of the pressure-flow characteristic of the tubing, for example by table lookup. The pressure at the mask  $p_m$  is then calculated in subtraction element 76 by subtracting the tube pressure loss from  $p_g(t)$ .

5

The pressure loss along tube 32 is then added to the desired set pressure at the mask  $p_{set}(t)$  in summation element 78 to yield the desired instantaneous pressure at the pressure generator 34. Preferably, the controller of the pressure generator 34 has a negative feedback input from the pressure transducer 70, so that the desired pressure from step 78 is achieved more accurately. The flow through the exhaust 42 is calculated from the pressure at the mask (calculated in element 76) from the pressure-flow characteristic of the exhaust in element 80, for example by table lookup. Finally, the mask flow is calculated by subtracting the flow through the exhaust 42 from the flow through the tubing 32, in subtraction element 82.

15

The methodology put into place by the controller 62 will now be described. In a first embodiment, there is a pressure response to apneas, but not to indicators of partial obstruction, and therefore snore detection bandpass filter 60 is not required.

20

An initial CPAP treatment pressure, typically 4 cmH<sub>2</sub>O, is supplied to the subject. The FLOW signal is processed to detect the occurrence of an apnea (as will presently be discussed) and, at the same time, the  $P_{mask}$  signal is recorded. When it is determined that an apnea has occurred its duration is recorded. At the same time  $P_{mask}$  is compared against a pressure threshold,  $P_u$ . If  $P_{mask}$  is at or above  $P_u$  the controller will act to maintain or reduce that pressure. If, on the other hand,  $P_{mask}$  is below  $P_u$ , the controller will act to increase the treatment pressure by an amount  $\Delta P$ .

25

In a preferred form,  $\Delta P$  is determined as follows:

$$\Delta P = [P_u - P]f(t_a) \quad (1)$$

30

where

$\Delta P$  is the change in pressure (cmH<sub>2</sub>O)

$P_u$  is the pressure threshold, which in an embodiment can be 10 cmH<sub>2</sub>O

35

$P$  is the current treatment pressure immediately before the apnea (cmH<sub>2</sub>O)

$t_a$  is the apnea duration (s)

$f(t_a)$  is a function that is a monotonically increasing function of  $t_a$ , zero for

$t_a = 0$

Fig.3 is a graphical representation of equation (1), showing a region below  $P_u$  where it is taken that an apnea is obstructive and demonstrating two cases of the  $\Delta P$  characteristic as a function of apnea duration (ie short and longer) such that  $\Delta P$  is an increasing function of apnea duration and a decreasing function of the current treatment pressure. Above  $P_u$ , it is taken that the apnea is non-obstructive, and  $\Delta P$  is held to be zero for all values of the current treatment pressure.

One form of the function  $f(t_a)$  is:

10

$$f(t_a) = \frac{rt_a}{\Delta P_{\max}} \quad (2)$$

In one embodiment the parameters can be:

15

$$r = 0.13 \text{ cmH}_2\text{O.s}^{-1}$$

$$\Delta P_{\max} = 6 \text{ cmH}_2\text{O}$$

Another form of the function  $f(t_a)$  is:

20

$$f(t_a) = 1 - \exp(-kt_a) \quad (3)$$

In one embodiment the parameter can be  $k = 0.02 \text{ s}^{-1}$

Fig. 4 is a graphical representation of equation (3) for the parameters given above.

25

The controller 62 implements the foregoing methodology using the following pseudo-code.

30

Set apnea duration to zero

Clear "start of breath" flag

Set initial CPAP pressure to 4 cmH<sub>2</sub>O.

Set maximum delta pressure due to apnea to 6 cmH<sub>2</sub>O.

Set top roll-off pressure to initial CPAP pressure plus maximum delta pressure due to apnea.

35

REPEAT

Sample mask airflow (in L/sec) at 50 Hz.

Calculate mask leak as mask airflow low pass filtered with a time constant of 10 seconds.  
Check for presence and duration of any apnea.  
Check for start of breath.  
5 IF start of breath flag set:  
    IF apnea duration greater than 10 seconds AND current CPAP pressure less than top roll-off pressure:  
        Set delta pressure for this apnea to (top roll-off pressure - current CPAP pressure)/maximum delta pressure due to apnea times 8 cmH<sub>2</sub>O per minute of apnea duration.  
10 Add delta pressure for this apnea to total delta pressure due to apnea, and truncate to maximum delta pressure due to apnea.  
        Reset apnea duration to zero.  
    ELSE  
15 Reduce total delta pressure due to apnea with a time constant of 20 minutes.  
    END  
    Set CPAP pressure to initial CPAP pressure plus total delta pressure due to apnea.  
20 Clear start of breath flag.  
    END  
END

25 This implementation is suitable for subjects in whom obstructive apneas are controlled at a CPAP pressure of less than 10 cmH<sub>2</sub>O. Increasing the maximum delta pressure due to apnea from 6 cmH<sub>2</sub>O to 10 cmH<sub>2</sub>O would permit the prevention of obstructive apneas in the majority of subjects, in exchange for an increase in undesirable pressure increases due to open airway apneas.

30 The procedure "Check for presence and duration of any apnea" can be implemented using the following pseudocode:

Calculate 2 second RMS airflow as the RMS airflow over the previous 2 seconds.  
Calculate longterm average RMS airflow as the 2 second RMS airflow, low pass  
35 filtered with a time constant of 300 seconds.  
IF 2 second RMS airflow is less than 25% of longterm average RMS airflow:  
    Mark apnea detected and increment apnea duration by 1/50 second.  
END

The procedure, "Check for start of breath" is implemented by the following pseudocode:

```
5      IF respiratory airflow is inspiratory AND respiratory airflow on previous sample
      was not inspiratory:
          Set "start of breath" flag.
      END
```

10 Fig. 5 shows the above method and apparatus in operation. The mask 30 was connected to a piston driven breathing simulator set to a normal respiratory rate and depth, and programmed to introduce a 20 second apnea once per minute from the 2nd minute to the 20th minute. In operation, the pressure remained at the initial pressure of 4 cmH<sub>2</sub>O until the first apnea, which led to a brisk increase in mask pressure. The pressure then  
15 decayed slightly during the subsequent 40 seconds of normal breathing. Subsequent apneas produced smaller increments, and the mask pressure settled out to approximately 9.5 cmH<sub>2</sub>O. In most actual patients, the number of apneas would reduce as the pressure increased. Because the pressure due to repetitive apneas cannot exceed 10 cmH<sub>2</sub>O, and most pressure-induced open airway apneas occur at very high pressures typically above  
20 10 cmH<sub>2</sub>O, this algorithm will not falsely or needlessly increase pressure in response to most pressure-induced open airway apneas, thus avoiding a vicious cycle of high pressure leading to open airway apneas leading to yet further pressure increase.

The above embodiment can be considerably improved by the addition of  
25 independent pressure increases in response to partial upper airway obstruction indicated by the presence of snoring or changes in the shape of the inspiratory flow-vs-time curve. In the majority of subjects, in whom substantial periods of snoring or flow limitation exist prior to any closed airway apneas, the CPAP pressure will increase in response to said snoring and/or changes in the shape of the inspiratory flow-vs-time  
30 curve, to a sufficient level to largely eliminate severe partial obstruction, without any apneas of any kind occurring. In those subjects in whom closed airway apneas appear with little or no prior period of partial obstruction, the first few apneas will produce a brisk increase in CPAP pressure as previously discussed, and in general this will provide sufficient partial support to the airway to permit periods of detectable partial  
35 obstruction, preventing any further apneas from occurring.

This second embodiment is implemented using the following pseudocode.

Set initial CPAP pressure to 4 cmH<sub>2</sub>O.  
Set apnea duration to zero  
Clear "start of breath" flag  
REPEAT every 1/50 of a second

5            Sample mask pressure (in cmH<sub>2</sub>O), mask airflow (in L/sec), and snore (1  
              unit corresponds loosely to a typical snore).  
              Calculate mask leak as mask airflow low pass filtered with a time constant  
              of 10 seconds.  
              Adjust snore signal for machine noise.

10           Check for presence and duration of any apnea.  
              Check for start of breath.  
              IF start of breath flag set:  
                 IF apnea duration greater than 10 seconds AND current CPAP  
                 pressure less than 10 cmH<sub>2</sub>O:  
15               Set delta pressure for this apnea to (10 - current CPAP  
                     pressure)/6 times 8 cmH<sub>2</sub>O per minute of apnea duration.  
                     Add delta pressure for this apnea to total delta pressure due to  
                     apnea, and truncate to 16 cmH<sub>2</sub>O  
                     Reset apnea duration to zero.

20           ELSE  
                 Reduce total delta pressure due to apnea with a time constant of  
                 20 minutes.  
              END  
              Calculate flow limitation index.

25           Calculate flow limitation threshold.  
              IF flow limitation index is less than said threshold:  
                 Set flow limitation delta pressure for this breath to 3 cmH<sub>2</sub>O  
                 times (threshold-flow limitation index).  
                 Add flow limitation delta pressure for this breath to total delta  
                 pressure due to flow limitation, and truncate to 16 cmH<sub>2</sub>O.

30           ELSE  
                 Reduce total delta pressure due to flow limitation with a time  
                 constant of 10 minutes.  
              END

35           Calculate mean snore for breath.  
              Calculate snore threshold.  
              IF mean snore exceeds said threshold:

set delta pressure due to snore for this breath to  $3 \text{ cmH}_2\text{O}$  times (mean snore for this breath - threshold).

Add delta pressure due to snore for this breath to total delta pressure due to snore, and truncate to 16 cmH<sub>2</sub>O.

5 ELSE

Reduce total delta pressure due to snore with a time constant of 10 minutes.

END

10                    Set CPAP pressure to 4 cmH<sub>2</sub>O plus total delta pressure due to apnea  
plus total delta pressure due to snore plus total delta pressure due to  
flow limitation, and truncate to 20 cmH<sub>2</sub>O.

Clear start of breath flag.

END

END

15

In the above implementation, apneas can only cause the CPAP pressure to rise as far as 10 cmH<sub>2</sub>O, but subsequently, indicators of partial obstruction can increase the CPAP pressure to 20 cmH<sub>2</sub>O, which is sufficient to treat the vast majority of subjects.

20           The procedure “Adjust snore for machine noise” is described by the following  
pseudocode:

Machine noise = K1 \* mask pressure + K2 \* mask pressure squared + K3 \* mask flow + K4 \* time derivative of mask flow + K5 \* time derivative of mask pressure.

$$\text{Adjusted snore signal} = \text{raw snore signal} - \text{machine noise.}$$

where the constants K1 to K5 are determined empirically for any particular physical embodiment, and for a particular machine may be zero. In other embodiments, blower fan speed measured with a tachometer or pressure at the blower may be used instead of mask pressure.

The procedure “Calculate flow limitation index” is described by the following pseudocode:

35

Identify the inspiratory portion of the preceding breath

Note the duration of inspiration.

Calculate the mean inspiratory airflow.

For each sample point over said inspiratory portion, calculate a normalized inspiratory airflow by dividing the inspiratory airflow by the mean inspiratory airflow.

5 Identify a mid-portion consisting of those sample points between 25% and 75% of the duration of inspiration.

Calculate the flow limitation index as the RMS deviation over said mid-portion of (normalized inspiratory airflow - 1)

10 The logic of the above algorithm is as follows: partial upper airway obstruction in untreated or partially treated Obstructive Sleep Apnea syndrome, and the related Upper Airway Resistance syndrome, leads to mid-inspiratory flow limitation, as shown in Fig. 6, which shows typical inspiratory waveforms respectively for normal and partially obstructed breaths, after scaling (normalizing) to equal mean amplitude and duration.

15 For a totally flow-limited breath, the flow amplitude vs. time curve would be a square wave and the RMS deviation would be zero. For a normal breath, the RMS deviation is approximately 0.2 units, and this deviation decreases as the flow limitation becomes more severe.

20 In some patients, it is not possible to prevent all upper airway obstruction, even at maximum pressure. In addition, there is a trade-off between the possible advantage of increasing the pressure in response to snoring and the disadvantage of increased side effects. This trade-off is implemented in procedure "calculate snore threshold" by looking up the snore threshold in the following table:

25

Pressure (cm H <sub>2</sub> O)	Threshold (snore units)	Description
< 10	0.2	very soft
10-12	0.25	
12-14	0.3	soft
14-16	0.4	
16-18	0.6	moderate
> 18	1.8	loud

For similar reasons, the procedure "calculate flow limitation threshold" sets the flow limitation threshold to a lower value corresponding to more severe flow limitation, if the pressure is already high or if there is a large leak:

30



IF mask leak is greater than 0.7 L/sec  
    set leak roll-off to 0.0  
ELSE if mask leak is less than 0.3 L/sec  
    set leak roll-off to 1.0  
5     ELSE  
        set leak roll-off to (0.7-mask leak)/0.4  
    END  
    Set pressure roll-off to (20-mask pressure)/16  
    Set flow limitation threshold to 0.15 times pressure roll-off times leak roll-off  
10

Some subjects will have occasional open airway apneas at sleep onset during stage 1 sleep and therefore at low pressure, and the above algorithm will incorrectly increase CPAP pressure in response to these events. However, such apneas are not usually repetitive, because the subject quickly becomes more deeply asleep where such events  
15 do not occur, and furthermore, the false pressure increments become smaller with repeated events. Once the subject reaches deeper sleep, any such falsely increased pressure will diminish. However, it is still advantageous to avoid falsely or needlessly increasing pressure in response to such sleep onset open airway apneas.

20 As previously discussed, one prior art method for avoiding unnecessary increases in pressure in response to open airway apneas is to determine the conductance of the airway during an apnea using the forced oscillation method, and only increase mask pressure if the conductance is less than a threshold. However, if the nasal airway is narrow or if the subject has lung disease, the airway conductance may be low even in  
25 the presence of an open airway and the forced oscillation method may still falsely increase pressure in response to open airway apneas. Conversely, the combination of the forced oscillation method with embodiments of the present invention has the added advantage that in most cases open airway apneas are correctly detected by the 'forced oscillation method', but in those cases where the forced oscillation method falsely  
30 reports a closed airway, the mask pressure will not increase above 10 cmH<sub>2</sub>O, thus preventing run-away increases in pressure. This is demonstrated in a third embodiment using the following pseudo-code:

35     Set apnea duration to zero  
    Clear "start of breath" flag  
    REPEAT every 1/50 of a second  
        Sample mask pressure (in cmH<sub>2</sub>O), mask airflow (in L/sec), and snore (1 unit corresponds loosely to a typical snore).

Calculate mask leak as mask airflow low pass filtered with a time constant of 10 seconds.  
Adjust snore signal for machine noise.  
Check for presence and duration of any apnea.  
5 IF apnea in progress:  
    measure conductance of airway using forced oscillation method.  
END  
Check for start of breath.  
IF start of breath flag set:  
10 IF apnea duration greater than 10 seconds AND current CPAP pressure less than 10 cmH<sub>2</sub>O AND airway conductance measured using forced oscillation method is less than 0.05 cmH<sub>2</sub>O/L/sec:  
    Set delta pressure for this apnea to (10 - current CPAP pressure)/6 times 8 cmH<sub>2</sub>O per minute of apnea duration.  
15 Add delta pressure for this apnea to total delta pressure due to apnea, and truncate to 16 cmH<sub>2</sub>O  
    Reset apnea duration to zero.  
ELSE  
    Reduce total delta pressure due to apnea with a time constant of  
20 20 minutes.  
END  
Calculate flow limitation index.  
Calculate flow limitation threshold.  
IF flow limitation index is less than said threshold:  
25 Set flow limitation delta pressure for this breath to 3 cmH<sub>2</sub>O times (threshold-flow limitation index).  
    Add flow limitation delta pressure for this breath to total delta pressure due to flow limitation, and truncate to 16 cmH<sub>2</sub>O.  
ELSE  
30 Reduce total delta pressure due to flow limitation with a time constant of 10 minutes.  
END  
Calculate mean snore for breath.  
Calculate snore threshold.  
35 IF mean snore exceeds said threshold:  
    set delta pressure due to snore for this breath to 3 cmH<sub>2</sub>O times (mean snore for this breath - threshold).

Add delta pressure due to snore for this breath to total delta pressure due to snore, and truncate to 16 cmH<sub>2</sub>O.

ELSE

5       Reduce total delta pressure due to snore with a time constant of 10 minutes.

END

Set CPAP pressure to 4 cmH<sub>2</sub>O plus total delta pressure due to apnea plus total delta pressure due to snore plus total delta pressure due to flow limitation, and truncate to 20 cmH<sub>2</sub>O.

10       Clear start of breath flag.

END

END

The procedure, "measure airway conductance using the forced oscillation method" can

15   be implemented using the following pseudocode:

Modulate airway pressure with an amplitude of 1 cmH<sub>2</sub>O peak to peak at 4 Hz.

Measure amplitude of airflow signal at 4 Hz.

Measure component of mask pressure signal at 4 Hz.

20   Set conductance equal to said airflow amplitude divided by said mask pressure amplitude.

An alternate expression of the combination of an embodiment of the invention and the forced oscillation method is:

25

IF

(a) the current pressure is low AND (b) the alternative method scores the airway as closed, THEN score the airway as closed.

ELSE IF

30   (a) the current pressure is high AND (b) the alternative method scores the airway as open, THEN score the airway as open.

ELSE

score the apnea as of unknown type.

35       A further possible arrangement is to substitute the 'cardiogenic method' for determining airway patency for the 'forced oscillation method', also disclosed in European Publication No. 0 651 971 A1 (and US Patent No. 5,704,345).

More complex variants of CPAP therapy, such as bi-level CPAP therapy or therapy in which the mask pressure is modulated within a breath, can also be monitored and/or controlled using the methods described herein.

## Claims:

1. A method for the administration of CPAP treatment pressure comprising the steps of:
  - 5 supplying breathable gas to the patient's airway at a treatment pressure;
  - determining a measure of respiratory airflow; and
  - determining the occurrence of an apnea from a reduction in the measure of respiratory airflow below a threshold, and, if having occurred,
    - (i) determining the duration of the apnea; and
    - 10 (ii) increasing the treatment pressure by an amount which is an increasing function of the duration of the apnea, and a decreasing function of the treatment pressure immediately before the apnea.
2. A method as claimed in claim 1, whereby the increase in treatment pressure is  
15 zero if the treatment pressure before the apnea exceeds a pressure threshold.
3. A method as claimed in claim 2, whereby the increase in pressure below the pressure threshold is an increasing function of the duration of the apnea, multiplied by the difference between the pressure threshold and the current treatment pressure.  
20
4. A method as claimed in claim 3, whereby said increasing function of apnea duration is linear on apnea duration.
5. A method as claimed in claim 3, whereby said increasing function of apnea  
25 duration is zero for zero apnea duration, and exponentially approaches an upper limit as apnea duration goes to infinity.
6. A method as claimed in any of claims 2 to 5, in which the pressure threshold is  
30 10 cmH<sub>2</sub>O.
7. A method as claimed in any one of the preceding claims, whereby the occurrence of an apnea is determined by the steps of:
  - calculating the RMS respiratory airflow over a short time interval;
  - calculating the RMS respiratory airflow over a longer time interval; and
  - 35 declaring an apnea if the RMS respiratory airflow over the short time interval is less than a predetermined fraction of the RMS respiratory airflow over the longer time interval.

8. A method as claimed in any one of the preceding claims, comprising the further step of reducing the treatment pressure towards an initial treatment pressure in the absence of a further apnea.
- 5 9. A method as claimed in any of the preceding claims, comprising the further steps of:  
in the absence of an apnea, determining the presence of partial obstruction; and  
if present, increasing the treatment pressure.
- 10 10. A method as claimed in claim 9, in which the presence of partial obstruction is determined from either (a) the shape of the patient's inspiratory flow vs time curve, or (b) from the presence of snoring, or (c) both.
11. A method as claimed in any one of claims 1 to 8, comprising the further steps of:  
15 if an apnea is occurring, determining whether the patient's airway is patent during the apnea; and  
if the airway is patent, setting the increase in treatment pressure to zero.
12. A method as claimed in claim 11, in which the patency of the airway is  
20 determined by the presence of a cardiogenic component in the respiratory airflow.
13. A method as claimed in claim 11, in which the patency of the airway is determined by the steps of:  
modulating the treatment pressure at a known frequency;  
25 measuring the component of the respiratory airflow at said modulation frequency;  
calculating the conductance of the airway as the ratio of the amplitude of said component of the respiratory airflow to the amplitude of the mask pressure modulation;  
and  
determining that the airway is patent if the conductance exceeds a conductance  
30 threshold.
14. CPAP treatment apparatus comprising:  
a controllable flow generator operable to produce breathable gas at a pressure elevated above atmosphere;  
35 a gas delivery tube coupled to the flow generator;  
a patient mask coupled to the tube to receive said breathable gas from the flow generator and provide said gas, at a desired treatment pressure, to the patient's airway;

a controller operable to receive input signals and to control operation of said flow generator and hence the treatment pressure; and

sensor means located to sense patient respiratory airflow and generate a signal input to the controller from which patient respiratory airflow is determined;

5 and wherein said controller is operable to determine the occurrence of an apnea from a reduction in said respiratory airflow below a threshold, and if having occurred, to determine the duration of said apnea and cause said flow generator to increase CPAP treatment pressure by an amount which is an increasing function of said apnea duration, and a decreasing function of the treatment pressure immediately prior to said apnea.

10

15. Apparatus as claimed in claim 14, wherein the increase in treatment pressure is zero if the treatment pressure before the apnea exceeds a pressure threshold.

15

16. Apparatus as claimed in claim 15, wherein the increase in pressure below the pressure threshold is an increasing function of the duration of the apnea, multiplied by the difference between the pressure threshold and the current treatment pressure.

20

17. Apparatus as claimed in claim 16, wherein said increasing function of apnea duration is linear on apnea duration.

18. Apparatus as claimed in claim 16, wherein said increasing function of apnea duration is zero for zero apnea duration, and exponentially approaches an upper limit as apnea duration goes to infinity.

25

19. Apparatus as claimed in any one of claims 14 to 18, in which the pressure threshold is 10 cmH<sub>2</sub>O.

30

20. Apparatus as claimed in any one of claims 14 to 19, wherein the controller is operable to determine the occurrence of an apnea, determined by:

calculating the RMS respiratory airflow over a short time interval;  
calculating the RMS respiratory airflow over a longer time interval; and  
declaring an apnea if the RMS respiratory airflow over the short time interval is less than a predetermined fraction of the RMS respiratory airflow over the longer time interval.

35

21. Apparatus as claimed in any one of claims 14 to 20, wherein the controller is further operable to cause reduction of the treatment pressure towards an initial treatment pressure in the absence of a further apnea.

22. Apparatus as claimed in any of claims 14 to 21, wherein the controller is further operable to, in the absence of an apnea, determine the presence of partial obstruction, and if present, to increase the treatment pressure.

5

23. Apparatus as claimed in claim 22, in which the presence of partial obstruction is determined from either (a) the shape of the patient's inspiratory flow vs time curve, or (b) from the presence of snoring, or (c) both.

10 24. Apparatus as claimed in any one of claims 14 to 21, wherein the controller is operable to:

if an apnea is occurring, to determine whether the patient's airway is patent during the apnea; and

if the airway is patent, to set the increase in treatment pressure to zero.

15

25. Apparatus as claimed in claim 24, in which the patency of the airway is determined by the controller detecting the presence of a cardiogenic component in the respiratory airflow.

20 26. Apparatus as claimed in claim 24, in which the patency of the airway is determined by the controller being operable to:

cause modulation of the treatment pressure at a known frequency;

measure the component of the respiratory airflow at said modulation frequency;

calculate the conductance of the airway as the ratio of the amplitude of said

25 component of the respiratory airflow to the amplitude of the mask pressure modulation; and

determine that the airway is patent if the conductance exceeds a conductance threshold.

30 27. CPAP treatment apparatus comprising:

a controllable flow generator operable to produce breathable gas to be provided to a patient at a treatment pressure elevated above atmosphere; and

a controller operable to receive input signals representing patient respiratory airflow, and to control operation of said flow generator and hence the treatment

35 pressure;

and wherein said controller is operable to determine the occurrence of an apnea from a reduction in said respiratory airflow below a threshold, and, if having occurred, to determine the duration of said apnea and cause said flow generator to increase CPAP



treatment pressure by an amount that is an increasing function of said apnea duration, and a decreasing function of the treatment pressure immediately prior to said apnea.

28. Apparatus as claimed in claim 27, wherein the increase in treatment pressure is zero if the treatment pressure before the apnea exceeds a pressure threshold.

29. Apparatus as claimed in claim 28, wherein the increase in pressure below the pressure threshold is an increasing function of the duration of the apnea, multiplied by the difference between the pressure threshold and the current treatment pressure.

10

30. Apparatus as claimed in claim 29, wherein said increasing function of apnea duration is linear on apnea duration.

31. Apparatus as claimed in claim 29, wherein said increasing function of apnea duration is zero for zero apnea duration, and exponentially approaches an upper limit as apnea duration goes to infinity.

15

32. Apparatus as claimed in any one of claims 27 to 31, in which the pressure threshold is 10 cmH<sub>2</sub>O.

20

33. Apparatus as claimed in any one of claims 27 to 31, wherein the controller is operable to determine the occurrence of an apnea is determined by:

calculating the RMS respiratory airflow over a short time interval;

calculating the RMS respiratory airflow over a longer time interval; and

25 declaring an apnea if the RMS respiratory airflow over the short time interval is less than a predetermined fraction of the RMS respiratory airflow over the longer time interval.

34. Apparatus as claimed in any one of claims 27 to 33, wherein the controller is further operable to cause reduction of the treatment pressure towards an initial treatment pressure in the absence of a further apnea.

30

35. Apparatus as claimed in any of claims 27 to 34, wherein the controller is further operable to, in the absence of an apnea, determine the presence of partial obstruction; and if present, increase the treatment pressure.

35

36. Apparatus as claimed in claim 35, in which the presence of partial obstruction is determined from either (a) the shape of the patient's inspiratory flow vs time curve, or (b) from the presence of snoring, or (c) both.

5 37. Apparatus as claimed in any one of claims 27 to 34, wherein the controller is operable to:

if an apnea is occurring, to determine whether the patient's airway is patent during the apnea; and

if the airway is patent, to set the increase in treatment pressure to zero.

10

38. Apparatus as claimed in claim 37, in which the patency of the airway is determined by the controller detecting the presence of a cardiogenic component in the respiratory airflow.

15 39. Apparatus as claimed in claim 37, in which the patency of the airway is determined by the flow generator being operable to modulate the treatment pressure at a known frequency; and the controller being operable to measure the component of the respiratory airflow at said modulation frequency, calculate the conductance of the airway as the ratio of the amplitude of said component of the respiratory airflow to the  
20 amplitude of the mask pressure modulation, and to determine that the airway is patent if the conductance exceeds a conductance threshold.




FIG. 1




FIG. 2




FIG. 3





FIG. 4






FIG. 6



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/AU 98/00950

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
Int Cl <sup>6</sup> : A61M 16/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) KEYWORD SEARCH		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) DERWENT		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 788805 A (De VILBISS HEALTH CARE, INC) 13 August 1997 Whole document	14-26
X	EP 774269 A (SIEMENS-ELEMA AB) 21 May 1997 Columns 4-7	14-26
X	WO 96/40337 A (NELLOR PURITAN BENNETT INC) 19 December 1996 Pages 6-8	14-26
X	EP 651971 A (RESCARE LTD) 10 May 1995 Pages 6-7, 11-14	14-26
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "( )" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 14 January 1999		Date of mailing of the international search report 14 DEC 1998
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (02) 6285 3929		Authorized officer  SUE THOMAS Telephone No.: (02) 6283 2454

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/AU 98/00950

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94/13349 A (PURITAN BENNETT CORP) 23 June 1994 Whole document	14-26

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU 98/00950

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report			Patent Family Member			
EP	788805	NONE				
EP	774269	JP	9168595			
WO	96/40337	NONE				
EP	651971	AU	77641/94	US	5704345	
WO	94/13349	AU	57441/94	EP	699084	US 5517983
		US	5715812			
END OF ANNEX						